Table 3 Analysis of target gene and protein expression 48 h after siRNA transfection of primary advanced CML cells

From: Additive antileukemia effects by GFI1B- and BCR–ABL-specific siRNA in advanced phase chronic myeloid leukemic cells

Gene expression

Control (mock)

BCR–ABL siRNA (54 p M)

GFI1B siRNA (175 p M)

BCR–ABL + GFI1B siRNA

MDR1

54.6±12.9

25.4±8.1***

42.8±12.9

17.6±10.8***

MPR

7.6±1.2

5.9±1.8*

6.8±1.5

3.0±1.2**

p21 CIP1/WAF1

4.4±0.8

4.6±0.7

5.3±0.8*

4.6±0.9

c-Myc

18.3±5.2

17.3±4.1

22.0±3.2

12.7±4.7*

Target expression

    

 CD243/p-gp

55.5±0.6

40.0±0.9**

39.1±1.2**

37.4±2.5**

 p-Crkl

76.0±5.1

45.8±9.1**

−

36.7±1.6**

 p-Tyr

85.6±2.7

46.9±1.4**

−

52.9±3.7**

  1. Abbreviations: BCR–ABL, breakpoint cluster region–Abelson murine leukemia oncogene; CML, chronic myeloid leukemia; siRNA, small interfering RNA.
  2. Genes expression normalized to GAPDH by real-time RT-PCR or protein levels by flow cytometry were measured up to fivefold and results are shown as mean + s.d.
  3. P-values are in ***P<0.001; in **P<0.01; and in *P<0.05, respectively.
Back to article page